KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) Equity Average (2016 - 2026)

West Pharmaceutical Services has reported Equity Average over the past 17 years, most recently at $3.1 billion for Q1 2026.

  • Quarterly Equity Average rose 14.93% to $3.1 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.1 billion through Mar 2026, up 14.93% year-over-year, with the annual reading at $2.9 billion for FY2025, 5.3% up from the prior year.
  • Equity Average was $3.1 billion for Q1 2026 at West Pharmaceutical Services, down from $3.1 billion in the prior quarter.
  • Over five years, Equity Average peaked at $3.1 billion in Q4 2025 and troughed at $2.3 billion in Q1 2022.
  • The 5-year median for Equity Average is $2.7 billion (2023), against an average of $2.7 billion.
  • Biggest five-year swings in Equity Average: grew 26.55% in 2022 and later fell 5.48% in 2024.
  • Tracing WST's Equity Average over 5 years: stood at $2.6 billion in 2022, then increased by 11.51% to $2.9 billion in 2023, then dropped by 5.48% to $2.7 billion in 2024, then rose by 14.59% to $3.1 billion in 2025, then dropped by 0.98% to $3.1 billion in 2026.
  • According to Business Quant data, Equity Average over the past three periods came in at $3.1 billion, $3.1 billion, and $3.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.